Statins, Obesity, and Hyperlipidemia

Slides:



Advertisements
Similar presentations
Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus.
Advertisements

DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
By: Kristin Izzo Preceptors: Elizabeth Koustis, MS, RD Pamela Jessup, MS, RD WADE PARK NUTRITION CLINIC.
Addressing the Challenges in Primary and Secondary Stroke Prevention
Statin Myopathy (AHA/ACC/NHLBI)
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Optimizing Statin Therapy
An Endocrinology Clinic in Dyslipidemia
Statin Selection Aimed to Reduce New-Onset DM Risk:
Omega-3 Prescriptions vs Supplements in Practice
The role of metabolic surgery in the management of obesity and t2dm
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
The "Metabolically Healthy Obese"
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Overview of Disparities
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patient 1: 53-Year-Old Man With CVD Risk Factors
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Understanding Statin Metabolism
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Metabolically Healthy Patients With Obesity
TNT Study: Baseline Characteristics of the Patients
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes Increases Risk of CVD
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
PCSK9 Inhibitors and Cardiovascular Outcomes
Statins and HIV:.
Radical New Concepts in Lipid Management
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Novel Approaches to T1D Management
Lipid Clinic Challenge
Aspirin and Cardioprevention in 2018
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Glucose Management and Statin Therapy
Add-On Therapy to Insulin in T1DM Management
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
Statins and Glucose Metabolism: An Endocrinology Perspective
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Glucose Management and Statin Therapy
Achieving Lipid Targets With PCSK9 Inhibition
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Statin Therapy in Patients With Insulin Resistance
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Statins, Obesity, and Hyperlipidemia

Primary Prevention Trials of Lipid-Altering Therapy Including Patients With Diabetes

Secondary Prevention Trials of Lipid-Altering Therapy Including Patients With Diabetes

Statins and Risk of Incident Diabetes

Effect of Statins on Glucose Metabolism

Adiposopathy and Insulin Resistance

NODM Is Not a Class Effect

Statins, NODM, and the Liver

Pitavastatin Has Neutral Effect on FBG Across Dose Range

Different Methods of Measuring Glucose

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat (Randomized Clinical Trial)

Gold Standard for Measuring Insulin Sensitivity and Liver Fat

Mean Baseline Characteristics

Results Insulin Sensitivity

Results Liver Fat

It Takes a Team

Conclusion

Abbreviations

Abbreviations (cont)